Trispecific antibodies targeting claudin-18.2 show cytotoxic activity in gastric cancer, suggesting a potential for clinical trials.
Claudin-18.2 is an overexpressed molecule in gastric cancer, which is why it is considered a potential therapeutic target. WO2024082060 describes trispecific antibodies directed against CDLN-18.2/CD3/CD28, and gastric cancer treatment method. These antibodies exhibit cytotoxic activity, in coculture with primary human CD3+ T lymphocytes, against gastric cancer cells expressing CLDN-18.2, as well as an inhibition of tumor growth rate in a murine model of gastric cancer. The trispecific structure, in particular the CD3 and CD28 binding domains, induce optimal co-stimulation of effector T cells, suggesting that these antibodies are potential candidates for clinical trials for the treatment of gastric cancer associated with high levels of CDLN-18.2 expression.
No takes yet. Share an insight, caveat, or question.
Flores-Robles et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: